*** Today’s Gainers***

TAMPA, Fla., Nov 1st, 2012 (eTeligis.com via COMTEX) (PINKSHEET: GNGR ) finished strong today closing up 77% on 22 million shares. Keep GNGR on your radar~!

(PINKSHEET: GNGR) Gunther Grant, Inc. Takes creative ideas in the early stages of development.  We further develop the idea just enough to bring the product to market where we can get a more realistic perspective as to whether or not the item warrants further development.  Using this strategy,  we can go from the idea stage to finished product quickly before investing significant capital which allows us to establish a sustainable competitive advantage.

Our objective is to capture more market share within the industries we serve, expand our geographic markets, grow our presence in the consumer industry and continually improve our results of operation. Our strategy to accomplish our objective is:

To capitalize on the strength of the Gunther Grant brands in order to win more business in our traditional markets and enter other markets.

To invest in people to meet the long-term growth in demand for our products, especially in emerging markets. Specifically, we intend to strengthen our sales and manufacturing capabilities where long-term estimates of demand for our products point to continued growth.

To always deliver products and solutions that enable our customers to achieve their objectives and that differentiate us from our competitors.

In order to effectively implement our strategy, we also must continually work to improve ourselves. These efforts include:

Investing in product testing and redesigning existing items to attract both new and consistent consumers.

Enhancing our manufacturing capacities, especially in connection with the design of our products, in order to be able to more quickly respond to existing and future customer demands.

Expanding our margins by implementing and expanding upon our operational efficiencies through a flexible manufacturing flow model and other cost efficiencies.

Get a full report on GNGR - http://www.globalinvestmentalert.com/land/analysisreport.html

(OTCQB: WNYN) Warp 9, Inc. early surge held on to close up 500% on 17 million shares. Big gainer.

(OTCQB: WNYN) Warp 9, Inc. is the premier provider of e-commerce services for midsize online sellers. Our Total Commerce Platform (TCP) is a cloud based, state-of-the-art e-commerce platform that provides online sellers with the highest level of functionality, performance and ease of use in the industry. Offered on a fully managed software-as-a-service model, Total Commerce Platform allows customers to focus on their core online businesses, rather than on technical implementations. We also offer industry leading mobile commerce solutions.

Warp 9 offers highly customized services at reasonable prices and we are always available to our online sellers, 24 hours a day, 7 days a week, 365 days a year. When you need us, we are there. When you grow, so does your scalable e-commerce platform. Your business is our business!

Get a free report on WNYN http://www.globalinvestmentalert.com/land/analysisreport.html

(OTCQB: AMBS) Amarantus BioSciences, Inc. had a huge day closing up 158% on 34 million shares.  ABMS may be the end of the week play. Keep it on your radar.

(OTCQB: AMBS) Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company focuses on developing its intellectual property and proprietary technology to develop drug candidates to treat human disease. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”).
MANF is a protein that corrects protein misfolding. Protein misfolding is one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research & development of MANF-based products as therapeutics for human disease. Amarantus’ lead MANF product development effort is centered on a therapy for Parkinson ’s disease.
The Company also owns an inventory of 88 cell lines that the Company refers to as PhenoGuard Cell Lines. MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. The Company believes that it may identify additional therapeutic proteins from its inventory of PhenoGuard Cell Lines.

Get a free report on AMBS - http://www.globalinvestmentalert.com/land/analysisreport.html

ABOUT GLOBALINVESTMENTALERT.COM:

Globalinvestmentalert.com offers a free newsletter featuring some of the best penny stock picks available. Our sole purpose is to find the best penny stock picks - period. To receive our awesome penny stock newsletter and alerts go to http://Globalinvestmentalert.com
 

Timing is everything when trading Penny Stocks. Be The First to Know by joining the GlobalInvestmentAlert.com newsletter. Our last four alerts have given our members over 1500% in gains.

For the Best Damn Stock Picks Subscribe to http://www.Globalinvestmentalert.com/

Disclosure: GlobalInvestmentAlert.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GlobalInvestmentAlert.com website, for complete risks and disclosures

Subscribe Here - http://www.Globalinvestmentalert.com/

Disclosure:  Globalinvestmentalert.com/ is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Global Investment Alert Inc has not been compensated for this report.

Please visit http://Globalinvestmentalert.com/ for complete risks and disclosures.

Contact: Globalinvestmentalert.com / mailto:info@globalinvestmentalert.com

Copyright (C) 2009 eTeligis.com, All Rights Reserved